Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It modulates immune cell activity, inhibits angiogenesis, and induces apoptosis of malignant plasma cells. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use across European and global markets.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cell proliferation and modulating the immune microenvironment to enhance anti‑tumor activity. - Multiple myeloma: reduces disease progression, prolongs progression‑free survival, and improves overall survival in adult patients. - Myelodysplastic syndromes with del(5q): corrects cytopenias, reduces transfusion requirements, and may achieve transfusion independence. - Mantle cell lymphoma: contributes to tumor control and response rates when combined with other agents in adult patients. - Combination therapy: used together with dexamethasone, proteasome inhibitors, or monoclonal antibodies to enhance treatment efficacy in the listed malignancies.

Lenalidomide may cause a range of adverse reactions, varying from mild to potentially life‑threatening. Common Side Effects: - Fatigue: mild to moderate tiredness - Nausea: occasional upset stomach and vomiting - Diarrhea: loose stools, sometimes watery - Rash: skin redness or itching - Constipation: difficulty passing stool - Peripheral neuropathy: tingling or numbness in extremities - Headache: mild to moderate head pain - Insomnia: difficulty sleeping Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: risk of serious blood clots - Neutropenia: severe reduction in white blood cells - Thrombocytopenia: low platelet count increasing bleeding risk - Secondary primary malignancies: rare occurrence of new cancers - Hepatotoxicity: elevated liver enzymes indicating liver injury - Cardiac arrhythmia: irregular heart rhythm

Before prescribing lenalidomide, clinicians should evaluate patient-specific factors and follow safety recommendations. - Pregnancy: contraindicated; teratogenic risk requires effective contraception for both sexes. - Thromboembolic risk: assess history and consider anticoagulation prophylaxis. - Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. - Renal impairment: adjust dose or monitor renal function in patients with decreased clearance. - Drug interactions: review concomitant medications for CYP450 inducers or anticoagulants. - Liver function: monitor transaminases periodically for signs of hepatotoxicity. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lenalidomide can interact with several medicines, altering efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (warfarin, direct oral anticoagulants): increased risk of thromboembolic events when combined. - Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects and raise infection risk. - Antiepileptic drugs (e.g., phenytoin): may lower lenalidomide levels, decreasing effectiveness. Moderate Interactions (Monitor Closely): - Corticosteroids (dexamethasone): may increase hematologic toxicity; monitor blood counts. - P-glycoprotein inhibitors (e.g., verapamil): can raise plasma levels modestly; observe for side effects. - Vaccines (live attenuated): reduced efficacy due to immunomodulation; consider timing. - Antibiotics (e.g., fluoroquinolones): may increase risk of QT prolongation; monitor ECG.